Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED. Hemophilia Therapy Innovation: Development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Seminars in Hematology, 41, Suppl 2: 1–18, 2004
Ewenstein B, Gomperts E, Pearson S, O’Banion, M: Inhibitor Development in Patients Receiving Recombinant Factor VIII (Recombinate rAHF/Bioclate): A Prospective Pharmacovigilance Study. Haemophilia, 10: 1–8, 2004
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Verlag Berlin Heidelberg
About this paper
Cite this paper
Gomperts, E. (2006). ADVATE Inhibitor Risk Profile: 18 Months post-Licensure. In: Scharrer, I., Schramm, W. (eds) 35th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28546-6_7
Download citation
DOI: https://doi.org/10.1007/3-540-28546-6_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28543-4
Online ISBN: 978-3-540-28546-5
eBook Packages: MedicineMedicine (R0)